September, 2024
September 2024
M T W T F S S
 1
2345678
9101112131415
16171819202122
23242526272829
30  
Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival
Sep 12, 2024, 17:16

Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival

Yüksel Ürün shared on X:

“Omitting the 5-FU bolus from regimens like FOLFOX, FOLFIRI, and FOLFIRINOX in metastatic GI cancers may reduce toxicity without impacting overall survival.”

GI cancers

 

Omission of 5-Fluorouracil Bolus From Multidrug Regimens for Advanced Gastrointestinal Cancers: A Multicenter Cohort Study

Authors: Chengwei Peng, Saad Saffo, Paul E. Oberstein, Michael Shusterman, Charlene Thomas, Daniel J. Becker, Jordan D. Berlin, Lawrence P. Leichman, Ben Boursi, Anil B. Nagar, Shun Yu

Yüksel Ürün: Omitting the 5-FU bolus from regimens in metastatic GI cancers may reduce toxicity without impacting overall survival

Source: Yüksel Ürün/X

More posts featuring Yüksel Ürün on oncodaily.com

Yüksel Ürün is a Medical Oncology professor at Ankara University School of Medicine in Turkey. His research focuses on genitourinary cancers, covering epidemiology, diagnosis, biomarkers, meta-analysis, and treatment outcomes. His dedication to patient care and research inspires positive change in the medical field.